{"id":29,"date":"2023-08-18T13:22:54","date_gmt":"2023-08-18T13:22:54","guid":{"rendered":"https:\/\/www.merckconnect.com\/doravirine\/?page_id=29"},"modified":"2025-05-27T10:37:33","modified_gmt":"2025-05-27T10:37:33","slug":"delstrigo-dosing-administration","status":"publish","type":"page","link":"https:\/\/www.merckconnect.com\/doravirine\/delstrigo-dosing-administration\/","title":{"rendered":"Dosing for DELSTRIGO"},"content":{"rendered":"\n\n

Dosing for DELSTRIGO\u00ae<\/sup> (doravirine\/lamivudine\/tenofovir<\/span> disoproxil fumarate)<\/strong><\/h1><\/div>\n\n\n\n\n
<\/div>\n\n\n\n

Recommended dosage:<\/strong> As a fixed-dose combination product containing 100 mg of doravirine (DOR), 300 mg of lamivudine (3TC), and 300 mg of tenofovir disoproxil fumarate (TDF). The recommended dosage in adults is one tablet taken orally once daily with or without food.<\/p>\n\n\n\n

<\/div>\n\n\n\n

DELSTRIGO is indicated as a complete regimen for the treatment of HIV-1 infection in adult patients with no prior ARV treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DELSTRIGO.<\/p>\n\n\n\n

<\/div>\n\n\n\n

In virologically suppressed PLWH, DELSTRIGO provides a complete regimen with convenient dosing.<\/strong><\/strong><\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n\n
<\/div>
\"\"\/<\/picture>

<\/p><\/figcaption><\/figure><\/div>\n<\/div>\n\n\n\n

\n

Once daily<\/strong><\/h3><\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n
<\/div>
\"\"\/<\/picture>

<\/p><\/figcaption><\/figure><\/div>\n<\/div>\n\n\n\n

\n

No food restrictions<\/strong><\/h3><\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n
<\/div>
\"\"\/<\/picture>

<\/p><\/figcaption><\/figure><\/div>\n<\/div>\n\n\n\n

\n

Booster free<\/strong><\/h3><\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n
<\/div>
\"\"\/<\/picture>

<\/p><\/figcaption><\/figure><\/div>\n<\/div>\n\n\n\n

\n

Can be used with a PPI<\/strong><\/h3><\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

Because DELSTRIGO is a fixed-dose combination tablet and the dosage of lamivudine and TDF cannot be adjusted, DELSTRIGO is not recommended in PLWH with estimated creatinine clearance less than 50 mL\/min.<\/strong><\/strong><\/h3><\/div>\n\n\n\n
<\/div>\n\n\n\n

Prior to or when initiating DELSTRIGO, test patients for HBV infections. <\/p>\n\n\n\n

<\/div>\n\n\n\n

Prior to or when initiating DELSTRIGO, and during treatment, on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus.<\/p>\n\n\n\n

<\/div>\n\n\n\n\n